About: Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China
Creator	Li, Changgui Wang, Dayan Shen, Shu Zhang, Chuntao Bai, Dongting Fan, Xingliang Li, Lili Shi, Dawei Wang, Junzhi Wu, Xing Chen,
Source	Medline; PMC
abstract	A novel avian influenza A H7N9-subtype virus emerged in China in 2013 and threatened global public health. Commercial kits that specifically detect avian influenza A (H7N9) virus RNA are urgently required to prepare for the emergence and potential pandemic of this novel influenza virus. The safety and effectiveness of three commercial molecular diagnostic assays were evaluated using a quality-control panel and clinical specimens collected from over 90 patients with confirmed avian influenza A (H7N9) virus infections. The analytical performance evaluation showed that diverse influenza H7N9 viruses can be detected with high within- and between-lot reproducibility and without cross-reactivity to other influenza viruses (H1N1 pdm09, seasonal H1N1, H3N2, H5N1 and influenza B). The detection limit of all the commercial assays was 2.83 Log(10) copies/μl [0.7 Log(10)TCID(50)/mL of avian influenza A (H7N9) virus strain A/Zhejiang/DTID-ZJU01/2013], which is comparable to the method recommended by the World Health Organization (WHO). In addition, using a WHO-Chinese National Influenza Center (CNIC) method as a reference for clinical evaluation, positive agreement of more than 98% was determined for all of the commercial kits, while negative agreement of more than 99% was observed. In conclusion, our findings provide comprehensive evidence for the high performance of three commercial diagnostic assays and suggest the application of these assays as rapid and effective diagnostic tools for avian influenza A (H7N9) virus in the routine clinical practice of medical laboratories.
has issue date	2015-09-11(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0137862
bibo:pmid	26361351
has license	cc-by
sha1sum (hex)	1e8ec294fcc4507fcc89872f84adcf4633bb10e6
schema:url	https://doi.org/10.1371/journal.pone.0137862
resource representing a document's title	Evaluation of Commercial Diagnostic Assays for the Specific Detection of Avian Influenza A (H7N9) Virus RNA Using a Quality-Control Panel and Clinical Specimens in China
has PubMed Central identifier	PMC4567293
has PubMed identifier	26361351
schema:publication	PLoS One
resource representing a document's body	covid:1e8ec294fcc4507fcc89872f84adcf4633bb10e6#body_text
is schema:about of	named entity 'USING' named entity 'Commercial' named entity 'virus' named entity 'cross-reactivity' named entity 'RNA' named entity 'DIAGNOSTIC' covid:arg/1e8ec294fcc4507fcc89872f84adcf4633bb10e6 named entity 'GLOBAL' named entity 'QUALITY' named entity 'H7N9' named entity 'EFFECTIVE' named entity 'OUR' named entity 'PERFORMANCE' named entity 'DIAGNOSTIC' named entity 'PROVIDE' named entity 'INFLUENZA VIRUS' named entity 'CLINICAL EVALUATION' named entity 'OBSERVED' named entity 'VIRUS' named entity 'RAPID' named entity 'FINDINGS' named entity 'CID' named entity 'COLLECTED' named entity 'REQUIRED' named entity 'DIVERSE' named entity 'DETERMINED' named entity 'REPRODUCIBILITY' named entity 'POSITIVE' named entity 'INFLUENZA' named entity 'INFLUENZA B' named entity 'USING' named entity 'ANALYTICAL' named entity 'SUBTYPE' named entity 'LOG' named entity 'MOLECULAR' named entity 'AVIAN INFLUENZA A' named entity 'CLINICAL PRACTICE' named entity 'H3N2' named entity 'DETECTION LIMIT' named entity 'CONCLUSION' named entity 'NATIONAL' named entity 'CHINESE' named entity 'PANDEMIC' named entity 'NOVEL' named entity 'PUBLIC HEALTH' named entity 'TO PREPARE' named entity 'EVALUATED' named entity 'THESE' named entity 'ADDITION' named entity 'BCL' named entity 'CHINA' named entity 'EFFECTIVENESS' named entity 'CONTROL' named entity 'EVALUATION' named entity 'STRAIN' named entity 'APPLICATION' named entity 'CONFIRMED' named entity 'NEGATIVE' named entity 'TOOLS' named entity 'POTENTIAL' named entity 'PANEL' named entity 'CLINICAL' named entity 'SPECIFIC' named entity 'VIRUS RNA' named entity 'AVIAN INFLUENZA A' named entity 'MEDICAL' named entity 'EVALUATION' named entity 'COMMERCIAL' named entity 'SPECIMENS' named entity 'QUALITY' named entity 'CHINA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software